Elliot Stieglitz

2.3k total citations
58 papers, 537 citations indexed

About

Elliot Stieglitz is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Elliot Stieglitz has authored 58 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Hematology, 26 papers in Molecular Biology and 20 papers in Genetics. Recurrent topics in Elliot Stieglitz's work include Acute Myeloid Leukemia Research (37 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). Elliot Stieglitz is often cited by papers focused on Acute Myeloid Leukemia Research (37 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Acute Lymphoblastic Leukemia research (11 papers). Elliot Stieglitz collaborates with scholars based in United States, Germany and Japan. Elliot Stieglitz's co-authors include Mignon L. Loh, Adam B. Olshen, Benjamin S. Braun, Christopher C. Dvorak, Jon Akutagawa, Daniel B. Lipka, Christian Flotho, Christoph Plass, Christine S. Higham and Julia Meyer and has published in prestigious journals such as Nature Communications, Blood and Scientific Reports.

In The Last Decade

Elliot Stieglitz

50 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elliot Stieglitz United States 13 292 245 135 127 92 58 537
Kelly S. Chien United States 12 501 1.7× 239 1.0× 186 1.4× 124 1.0× 104 1.1× 107 654
Sebastian Vosberg Germany 10 288 1.0× 227 0.9× 75 0.6× 154 1.2× 157 1.7× 20 570
Montserrat Torrebadell Spain 10 354 1.2× 224 0.9× 189 1.4× 114 0.9× 144 1.6× 21 571
Karin Nebral Austria 12 294 1.0× 178 0.7× 72 0.5× 284 2.2× 83 0.9× 31 513
Jochen Casper Germany 13 313 1.1× 241 1.0× 85 0.6× 139 1.1× 145 1.6× 39 701
Michel Zwaan Netherlands 8 335 1.1× 320 1.3× 78 0.6× 263 2.1× 153 1.7× 19 715
Cosimo Cumbo Italy 15 279 1.0× 254 1.0× 162 1.2× 100 0.8× 77 0.8× 45 566
Giuseppina Tota Italy 16 269 0.9× 261 1.1× 153 1.1× 96 0.8× 77 0.8× 41 571
Rob S. Sellar United Kingdom 11 300 1.0× 154 0.6× 135 1.0× 52 0.4× 91 1.0× 22 482
Angela Minervini Italy 14 214 0.7× 221 0.9× 128 0.9× 90 0.7× 62 0.7× 38 483

Countries citing papers authored by Elliot Stieglitz

Since Specialization
Citations

This map shows the geographic impact of Elliot Stieglitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elliot Stieglitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elliot Stieglitz more than expected).

Fields of papers citing papers by Elliot Stieglitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elliot Stieglitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elliot Stieglitz. The network helps show where Elliot Stieglitz may publish in the future.

Co-authorship network of co-authors of Elliot Stieglitz

This figure shows the co-authorship network connecting the top 25 collaborators of Elliot Stieglitz. A scholar is included among the top collaborators of Elliot Stieglitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elliot Stieglitz. Elliot Stieglitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Popescu, Bogdan, Matthew F. Jones, Cheryl A.C. Peretz, et al.. (2025). Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 147(3). 276–289. 1 indexed citations
2.
Westover, Tamara, Michael Walsh, Sherif Abdelhamed, et al.. (2025). Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions. PubMed. 2(2). 100093–100093.
3.
4.
Stieglitz, Elliot & Lauren Pommert. (2024). Risk-stratified Treatment for Pediatric Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia. The Hematologist. 21(2).
5.
6.
Stieglitz, Elliot, Alex G. Lee, Steven P. Angus, et al.. (2024). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group. Cancer Discovery. 14(9). 1590–1598. 4 indexed citations
7.
Agrawal, Anurag K., Carla Golden, Benjamin J. Huang, et al.. (2023). Venetoclax in combination with chemotherapy as treatment for pediatric advanced hematologic malignancies. Pediatric Blood & Cancer. 70(6). e30335–e30335. 5 indexed citations
8.
Stieglitz, Elliot, Alex Lee, Steven P. Angus, et al.. (2023). Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group. Blood. 142(Supplement 1). 74–74. 2 indexed citations
9.
Stieglitz, Elliot, Christine Gu, Michelle Richardson, et al.. (2023). Tretinoin Enhances the Effects of Chemotherapy in Juvenile Myelomonocytic Leukemia Using an Ex Vivo Drug Sensitivity Assay. JCO Precision Oncology. 7(7). e2300302–e2300302. 1 indexed citations
10.
Pasupuleti, Santhosh Kumar, Lakshmi Reddy Palam, Sheng Liu, et al.. (2023). Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia. Molecular Therapy. 31(4). 986–1001. 4 indexed citations
11.
Popescu, Bogdan, Carlos Stahlhut, Bianca J. Lee, et al.. (2023). Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. Cell Reports Medicine. 4(11). 101290–101290. 6 indexed citations
12.
Stieglitz, Elliot, et al.. (2023). Too many white cells—TAM, JMML, or something else?. Hematology. 2023(1). 37–42.
13.
Palam, Lakshmi Reddy, Santhosh Kumar Pasupuleti, Victoria Jideonwo, et al.. (2022). Inhibition of BTK and PI3Kδ impairs the development of human JMML stem and progenitor cells. Molecular Therapy. 30(7). 2505–2521. 2 indexed citations
14.
Pasupuleti, Santhosh Kumar, et al.. (2021). Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse. Blood. 138(Supplement 1). 1471–1471. 1 indexed citations
15.
Meyer, Julia, Aaron Hechmer, Mignon L. Loh, et al.. (2021). Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia. 36(1). 279–282. 9 indexed citations
16.
Smith, Stephen B., Beng Fuh, Arun Rangaswami, et al.. (2021). Therapy‐related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Pediatric Blood & Cancer. 69(5). e29499–e29499. 1 indexed citations
17.
Lee, Alex G., Marcus R. Breese, Charles Zaloudek, et al.. (2020). Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature. JCO Precision Oncology. 4(4). 1321–1332. 5 indexed citations
18.
Friend, Brian D., Alexis Melton, Kristin A. Shimano, et al.. (2019). The impact of total body irradiation‐based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood & Cancer. 67(2). e28079–e28079. 17 indexed citations
19.
Dvorak, Christopher C., Prakash Satwani, Elliot Stieglitz, et al.. (2018). Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood & Cancer. 65(7). e27034–e27034. 23 indexed citations
20.
Stieglitz, Elliot, Camille Troup, John Haliburton, et al.. (2014). Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood. 125(3). 516–524. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelly S. Chien Breakdown of academic impact, for papers by Sebastian Vosberg Breakdown of academic impact, for papers by Montserrat Torrebadell Breakdown of academic impact, for papers by Karin Nebral Breakdown of academic impact, for papers by Jochen Casper Breakdown of academic impact, for papers by Michel Zwaan Breakdown of academic impact, for papers by Cosimo Cumbo Breakdown of academic impact, for papers by Giuseppina Tota Breakdown of academic impact, for papers by Rob S. Sellar Breakdown of academic impact, for papers by Angela Minervini
Rankless by CCL
2026